SAS
TEVA icon

Stelac Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

Stelac Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,545
Closed -$326K – 82
2017
Q3 		$326K Buy
+18,545
New +$417K 0.1% 53

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Stelac Advisory Services's TEVA Position: Q4 2017 in Review

Stelac Advisory Services sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 18,545 shares — an estimated $326K sold.

Stelac Advisory Services first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $326K in Q3 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Stelac Advisory Services reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Stelac Advisory Services sold 18,545 Teva Pharmaceuticals shares in Q4 2017, an estimated $326K.
  • Stelac Advisory Services first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Stelac Advisory Services's Teva Pharmaceuticals position peaked at $326K in Q3 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Stelac Advisory Services's 13F filing for Q4 2017, filed 12 Feb 2018.